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Abstract
Background:  Transforming growth factor-β (TGF-β) is a key mediator in establishing liver
fibrosis. Therefore, TGF-β as a causative agent may serve as a primary target for antifibrotic gene
therapy approaches. We have previously shown that the adenoviral delivery of a transgene
constitutively expressing a TGF-β1 antisense mRNA blocks TGF-β synthesis in culture-activated
hepatic stellate cells and effectively abolishes ongoing fibrogenesis in vitro.
Methods: Ligature of the common bile duct was used to induce liver fibrosis in rats. The effect of
the TGF-β1 antisense on fibrogenesis was analyzed in this model of liver injury.
Results: In the present study, we demonstrate that the adenoviral vector directs the synthesis of
mRNA quantities that are approximately 8000-fold more abundant than endogenous TGF-β1
mRNA. In experimentally injured rat livers induced by ligature of the common bile duct, a model
for persistent fibrogenesis and cirrhosis, administration of the adenoviral vector abrogates TGF-β-
enhanced production of collagen and α-smooth muscle actin. Furthermore, the number of cells
positive for α-smooth muscle actin resulting from active recruitment of activated hepatic stellate
cells around the bile ductular structures was significantly reduced in animals after application of
Ad5-CMV-AS-TGF-β1. However, the observed elevated serum levels of aspartate
aminotransferase, alanine aminotransferase, and bilirubin induced in this obstructive liver injury
model were not significantly altered in the presence of the TGF-β antagonist.
Conclusion: Taken together, our data provides in vivo evidence that the delivery of TGF-β1
antisense mRNA specifically abolishes the diverse effects of direct TGF-β function in ongoing liver
fibrogenesis. Therefore, we conclude that the expressed transgene is therapeutically useful for
inhibition of TGF-β effects in diverse applications, ranging from clarification of TGF-β function in
the course of liver injury to the development of novel gene therapeutic approaches.
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Background
Transforming growth factor-β1 (TGF-β1) is a multifunc-
tional cytokine involved in the regulation of cell prolifer-
ation, differentiation, extracellular matrix production,
wound healing and tissue repair [1]. In liver fibrogenesis,
TGF-β is of crucial importance triggering excessive forma-
tion and deposition of connective tissue matrix molecules
[2]. Typically, during hepatic injury resting hepatic stellate
cells (HSC) undergo cellular activation which in term is
associated with proliferation, increased contractile activ-
ity, fibrogenesis, changes in matrix protease activity, loss
of intracellular retinoid storage, production of cytokines,
and phenotypic transformation to a myofibroblast-like
morphology [3]. TGF-β binds and signals through distinct
heteromeric transmembrane receptors, including type I
(TβRI) and type II (TβRII) serine/threonine kinase recep-
tors [4]. Activation of this complex is initiated by binding
of TGF-β to TβR-II triggering heteromerization with and
transphosphorylation of TβRI. The signal is then propa-
gated through phosphorylation of receptor associated
Smad2 and 3 and oligomerization with the common
mediator Smad4. Complexes of phosphorylated Smad2
or 3 and Smad4 translocate into the nucleus, where they
affect transcription of target genes via direct DNA binding
or by association with numerous DNA binding proteins
[5,6]. Aberrant expression of TGF-β is involved in a
number of disease processes, including fibrosis and
inflammation. This is demonstrated in transgenic mice,
which develop multiple tissue lesions including hepatic
fibrosis as a consequence of elevated levels of TGF-β [7–
9]. This evidence provides a rationale for targeting TGF-β
as an antifibrotic agent. In the last decade, significant
advances in cell biology have opened several ways to
inhibit TGF-β action. One experimental approach to
block TGF-β signaling is the local expression of a soluble,
dominant negative TβRII [10]. During liver injury, this
strategy is appropriate to prevent progression of fibrosis,
to inhibit matrix synthesis and to decrease cell prolifera-
tion [11–13] indicating that prevention of fibrosis
through anti-TGF-β treatment could have some future
therapeutic value. Treatment with short DNA antisense
oligonucleotides was shown to suppress TGF-β1 function
in an interstitial fibrosis model and in balloon catheter
injury [14,15]. Impressively, overexpression of antagonis-
tic Smad7, a natural antagonist of TGF-β signaling was
sufficient to prevent bleomycin-induced pulmonary fibro-
sis in mice [16].
We have recently demonstrated that adenoviral delivery of
an antisense RNA complementary to the 3' coding
sequence of rat TGF-β1 is able to suppress the synthesis of
TGF-β1 in culture-activated rat HSC [17]. The adenoviral
vehicle directs high-level expression of the transgene and
the transduced antisense was found to block TGF-β syn-
thesis as assessed by immunoprecipitation, western blot
analysis, quantitative TGF-β1 ELISA, and cell proliferation
assays. Moreover, we found that the construct was able to
induce differential activity of TGF-β1 responsive genes
indicating that the delivery of this mRNA, complementary
to endogenous TGF-β transcript, offers a feasible approach
to block TGF-β1 signaling in this experimental in vitro
model for liver fibrogenesis [17].
In the present study, we demonstrate that infection with
Ad5-CMV-AS-TGF-β1 induces cellular mRNA quantities
that are approximately 8000-fold abundant over endog-
enous TGF-β1 mRNA. In rats with ligature of the common
bile duct (BDL), an experimental model of liver fibrogen-
esis, the administration of the adenoviral vector abrogates
the production of collagen and α-smooth muscle actin (α-
SMA) but has no significant impact on serum levels of
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), or bilirubin. Taken together, our data gives
evidence that the transfer of the TGF-β1 antisense is suffi-
cient to specifically abolish ongoing liver fibrogenesis but
does not interfere with the injury per se.
Methods
Isolation and culture of liver cells
Hepatic stellate cells (HSC) were isolated from male
Sprague-Dawley rats following a standard procedure with
slight modifications [18,19]. Briefly, livers were perfused
with pronase and collagenase and the resulting cell sus-
pensions were filtered through a nylon mesh, centrifuged
and washed in ice cold Hanks buffered standard saline
(HBSS; PAA Laboratories GmbH, Linz, Austria) contain-
ing 0.25% (w/v) BSA. HSC were further purified by a sin-
gle-step density gradient centrifugation with 8.25% (w/v)
Nycodenz®  (Nycomed Pharma, Oslo, Norway) as
described in detail elsewhere [20,21] and seeded in Dul-
beccos's modified Eagle medium (DMEM; Bio Whittaker
Europe, Verviers, Belgium) supplemented with 10% (v/v)
fetal calf serum (FCS; Seromed, Biochrom KG, Berlin, Ger-
many), and 4 mM L-glutamine (ICN Biomedicals Inc.,
Aurora, Ohio). Additionally, the culture medium was sup-
plemented with penicillin (100 IU/ml) and streptomycin
(100 µg/ml).
RNA isolation and northern blot analysis
Isolation and Northern blot analysis of total cellular RNA
from HSC was carried out as described previously [19].
Briefly, equal amounts (5 µg) of total RNA were separated
by electrophoresis on a 1.2% (w/v) denaturing agarose
gel, transferred to a Hybond-N membrane (Amersham
Pharmacia, Braunschweig, Germany), and fixed by baking
for 2 hours at 80°C. Blots were hybridized with [α-32P]-
dCTP-labeled random primed probes (Amersham) and
autoradiographs were exposed to Kodak X-OMAT AR
films using intensifying screens. As an internal standard
for equal gel loading the blots were re-hybridized with aBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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cDNA specific for glyceraldehyde-3-phosphate dehydro-
genase (GAPDH).
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting
Whole cell protein extracts were prepared in RIPA buffer
[20 mM Tris-HCl (pH 7.2), 0.15 M NaCl, 2% (v/v) NP-40,
0.1% (w/v) SDS, 0.5% sodium deoxycholate] and concen-
trations were quantified using the Micro BCA protein
assay reagent kit (Pierce, Rockford, IL). Equal amounts of
protein were resolved by reducing SDS-PAGE (Novex,
Groningen, The Netherlands). For immunoblotting, pro-
teins were electroblotted onto nitrocellulose membranes.
Membrane blocking and incubation with antibodies were
performed as described previously [17]. α-SMA was
detected with the monoclonal mouse antibody clone
asm-1 (Roche Diagnostics, Mannheim, Germany) fol-
lowed by incubation with horseradish peroxidase (HRP)-
conjugated anti-mouse IgG (Santa Cruz Biotech., Santa
Cruz, CA) and the supersignal chemiluminescent sub-
strate (Pierce).
Adenoviral vector construction and virus purification
The recombinant E1-deleted adenoviral vectors constitu-
tively expressing the enhanced green fluorescent protein
(EGFP) or rat antisense TGF-β1 were generated as
described previously [17,22]. Adenoviral particles were
purified by a standard CsCl density protocol followed by
a membrane based ion exchange chromatography for
purification of adenoviral particles (BD Bioscience,
CLONTECH, Palo Alto, CA). Adenoviral titers were spec-
trometrically determined and appropriate aliquots were
stored at -80°C until use.
Experimental model of liver fibrosis
Male Sprague-Dawley rats (245.6 ± 10.8 g) were injected
twice (at day 0 and day 7) with recombinant adenoviruses
(1 × 1010 pfu/kg) or phosphate buffered saline via the tail
vein. At day two, the common bile ducts were double
ligated under halothane anesthesia. Rats were sacrificed
after 12 days, and pieces of the livers were fixed in 10%
formalin for histological examination or frozen immedi-
ately in liquid nitrogen and stored at -80°C for RNA iso-
lation. Measurements of AST, ALT, and bilirubin were
performed from blood samples following standard proto-
cols. The study as presented is in compliance with the Ger-
man Animal Protection Act, and was approved by the
local committee for care and use of laboratory animals at
the RWTH-University Hospital. Experiments applying
adenoviral constructs to cells or animals are covered by
permission of the Landesumweltamt Nordrhein-West-
falen (Az. 521-K-1.59/99).
Histological scoring of liver fibrosis in rats
Morphological evaluation of induced liver fibrogenesis
was performed using the semi-quantitative fibrotic focus
score proposed for staging and grading of histopathologi-
cal lesion of chronic hepatitis in humans [23]. Briefly,
pieces of left liver lobules were fixed in 10% formalin and
stained with hematoxylin/eosine for identification of
lesions. In the stained sections, the lesions were defined as
follows: absence of lesions = 0; occasional small localized
lesions with fibrous expansion of some portal areas = 1;
thickening of liver septa with fibrous expansion of most
portal areas = 2; and thickened continuous fibrous areas
with periportal rounding and occasional portal to portal
bridging = 3. The liver sections were coded and independ-
ently examined in a blinded manner by two different
pathologists.
Immunohistochemistry
Liver tissues were fixed in 4% paraformaldehyde and
embedded in paraffin and 1.5-µm sections were prepared.
For immunohistochemistry, the sections were treated
with xylene and rehydrated with decreasing graded etha-
nol washes. For α-SMA staining, the slides were treated
with a polyclonal anti-rat α-SMA (Roche Diagnostics) fol-
lowed by HRP-conjugated secondary anti-rabbit antibody
(DAKO, Hamburg, Germany). α-SMA staining was
detected using the DAB substrate (Vector Laboratories,
Burlingame, CA) and sections were counterstained with
eosine.
Sirius red staining
Collagen staining was performed as described previously
[24]. Briefly, liver sections were deparaffinized and the
slides were incubated for 30 min in a solution of saturated
picric acid containing 0.1% direct red 80 and 0.1% Fast
Green FCF. Stained slides were washed in running dis-
tilled water, dehydrated, mounted, and examined by light
microscopy.
Quantitative real-time PCR
Total RNA (2 µg) isolated from untreated HSC, and HSC
infected with Ad5-CMV-EGFP or Ad5-CMV-AS-TGF-β1
was reversed transcribed in 20 µl using the SuperscriptII
Reverse Transcriptase (Invitrogen, Karlsruhe, Germany)
and random hexamer primer according to the manufac-
turer's instructions. 2-µl aliquots of first strand cDNA
samples were subjected to PCR in a volume of 20 µl using
2 µM forward and reverse primer, 2 µl dNTPs (each 10
mM dATP, dCTP, dGTP, dTTP), 1x PCR reaction buffer,
and 2.5 U Taq DNA polymerase (Roche Diagnostics). All
PCR-assays were conducted in capillaries on a LightCycler
system (20 µl-reaction volume) using the LC-FastStart
DNA Master SYBR Green I kit (Roche Diagnostics). Con-
ditions were: 95°C for 10 min (initial denaturation),
95°C for 10 s, 66°C for 5 s, 72°C for 15 s (45 cycles) andBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
Page 4 of 12
(page number not for citation purposes)
72°C for 1 min (final extension). Primer P1 [5'-d-(TGG
CGT TAC CTT GGT AAC C)-3'] and P2 [5'-d(GGT GTT
GAG CCC TTT CCA G)-3'] directed the amplification of a
277-bp fragment of endogenous TGF-β1. The same PCR
conditions with primer P3 [5'-d(CAA GGT CCT TGC CCT
CTA)-3'] and P4 [5'-d(GCG CAC AAT CAT GTT GGA CA)-
3'] annealing to both endogenous TGF-β1 and antisense
TGF-β1 were taken to amplify a 145-bp fragment. For
amplification of AS-TGF-β1 specific transcripts we used
primer P5 [5'-d(CGG TGA TGC GGA AGC ACC CG)-3']
and P6 [5'-d(CCT CTA CAA ATG TGG TAT GG)-3'] direct-
ing the amplification of a hybrid amplicon containing
sequences specific for TGF-β1 and the downstream SV40-
polyadenylation signal. After PCR, products were melted
in a temperature transition procedure from 65°C to 95°C
in steps of 0.1°C/s and fluorescence signals were meas-
ured and plotted online against the temperature. The sec-
ond derivative maximum method was taken to determine
the crossing points automatically for individual samples
and relative amounts of target gene was calculated based
on the crossing point analysis (LC-software, version 5.32).
Results
High-level expression and antifibrotic capacity of the 
antisense TGF-β1 device
We cloned the adenoviral construct Ad5-CMV-AS-TGF-β1
expressing an antisense (AS) complementary to the 3'-
portion of rat TGF-β1 mRNA and a control virus express-
ing EGFP [17,22]. Both transgenes are driven by the
human cytomegalovirus (CMV) immediate-early gene 1
enhancer/promoter and are fused to the SV40 early mRNA
polyadenylation signal (Fig. 1A). In culture-activated
HSC, Ad5-CMV-AS-TGF-β1 is able to direct high-level
expression of the antisense mRNA (Fig. 1B, top). In agree-
ment with the functionality of the transgene the level of
colα1(I) mRNA, a classical marker of fibrosis, was signifi-
cantly reduced in transdifferentiating HSC infected with
the transgene (Fig. 1B, middle). The reduction of colα1(I)
mRNA was specific for the expressed transgene and was
not observed in cells infected with other recombinant ade-
noviruses. To assess the relative abundance of the
expressed AS-mRNA over endogenous TGF-β1 transcripts
we established SYBR Green I-based real-time quantitative
PCR procedures. The assays were conducted on a LightCy-
cler (LC) and amplification of transcripts for TGF-β or
both, TGF-β- and AS-TGF-β, were performed by specific
primer combinations (Fig. 1C). Compared to mock- or
control virus-infected cells, the obtained fluorescent sig-
nals were higher in HSC infected with Ad5-CMV-AS-TGF-
β1. Typically, the logarithmic amplification phase in sam-
ples taken from these cells were reached two cycles earlier
suggesting that endogenous TGF-β transcripts were
approximately four fold more abundant in these cells
(Fig. 1D). This finding is consistent with our previous
observation that the endogenous TGF-β1 mRNA is stabi-
lized by the transgene most likely because under cellular
environment mRNA/mRNA hybrids are resistant to the
attack of ribonuclease H, the key enzyme of ribonucleic
acid degradation. Simultaneous amplification of both
transcripts (TGF-β and AS-TGF-β) revealed that equal flu-
orescent signals were obtained approximately 13 cycles
earlier in samples of Ad5-CMV-AS-TGF-β1-infected cells
than in the controls (untreated HSC or HSC infected with
Ad5-CMV-EGFP). Provided that the PCR efficiencies dur-
ing the logarithmic amplification phases in each probe
equals two, this points to an 8000-fold excess of the AS-
mRNA relative to endogenous TGF-β1 mRNA in these
cells. With the knowledge about the high abundance of
the antisense and the recent demonstration that the trans-
gene is able to block synthesis of TGF-β1 in vitro [17], we
next asked whether the transgene is useful for the treat-
ment of hepatic fibrosis.
Ligature of the common bile buct induces fibrosis in rat
Hepatic fibrosis in rats can be experimentally induced by
double ligature of the common bile duct (BDL) for several
weeks or months resulting in morphological changes in
liver tissue comparable to those seen in human biliary
fibrosis [25–27]. Since the first reports of this experimen-
tal model for liver injury it has been used in many labora-
tories to study the cellular and biological changes during
liver fibrogenesis. The prolonged bile duct obstruction has
many advantages over the experimentally induced cirrho-
sis generated by multiple doses of the CCl4 or dimethyln-
itrosamine (DMN), because the individual response of
animals to these hepatoxins is variable, the mortality is
high, and it takes a relatively long time to produce persist-
ent fibrosis or cirrhosis. However, to validate new thera-
peutic strategies in this obstructive model and to allow
reproducibility between different laboratories it is neces-
sary to follow standard operating procedures. In our labo-
ratory we use male rats of the Sprague-Dawley strain
weighed approximately 250 g that are fed with a standard
chow and having free access to trap water. Surgeries for lig-
ature of the common bile duct are performed under deep
Ketamin-Rompun anesthesia. Following our protocol, the
abdominal wall of the animals is first shaved and the
abdomen is cut with a scalpel through a median line (Fig.
2A). Then, the abdominal cavity is opened, and selvages
are stretched and fixed with two sterile high-grade steel
tweezers (Fig. 2B). Afterwards, the liver lobules are turned
down and intestines are carefully pulled out to uncover
the bile duct (Fig. 2C). The extrahepatic common bile
duct is pulled out, fixed with forceps, and obstructed with
a piece of string (Fig. 2D). A second ligature is introduced
in a distance of approximately 1 cm (Fig. 2E). Liver is
replaced into its correct position within the abdominal
cavity and the abdomen is closed with sutures (Fig. 2F).
Sham-operated rats are treated in the same manner except
that the bile duct is not ligated. After 12 days, tremendousBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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differences between sham-operated and BDL-ligated rats
in regard to their liver appearance are obvious (compare
Figs. 2G, 2H). In general, the obstruction induces bile duct
proliferation and inflammatory/fibrotic reactions with
concomitant formation of oedema and fibrotic nodules
on the surface of corresponding livers. To monitor ongo-
ing fibrogenesis we routinely determine the concentra-
tions of bilirubin, and the activities of serum AST and ALT
from blood samples aspirated from the tail vein. In nor-
mal controls (n = 65) levels for individual parameters
were measured as 0.14 ± 0.05 mg/dl (bilirubin), 53.49 ±
17.31 U/l (AST), and 28.18 ± 7.84 U/l (ALT), respectively
Adenoviral expression and antifibrotic capacity of an AS-TGF-β1 mRNA in culture-activated HSC Figure 1
Adenoviral expression and antifibrotic capacity of an AS-TGF-β1 mRNA in culture-activated HSC. (A) Sche-
matic representation of Ad5-CMV-AS-TGF-β1 [17] and Ad5-CMV-EGFP [22] expressing their transgene under regulatory con-
trol of the human cytomegalovirus immediate-early gene 1 promoter (CMV). A SV40 polyadenylation signal (pA) downstream 
of each transgene directs the proper processing of the 3' end of the corresponding mRNA. (B) Northern blot analysis from 
untreated HSC (1), and HSC infected with Ad5-CMV-EGFP (2) or Ad5-CMV-AS-TGF-β1 (3). The blot was subsequently 
hybridized with 32P-labelled probes specific for TGF-β1, colα1(I), and GAPDH. (C) Strategy for relative quantification of tran-
scripts specific for TGF-β1 or AS-TGF-β1. Primer P1 and P2 specific for endogenous TGF-β1, or primer P3 and P4 specific for 
both, endogenous TGF-β1 and AS-TGF-β1, were used in RT-PCR. The assay was conducted in a LightCycler system. (D, E) 
RNA isolated from untreated HSC (1), and HSC infected with Ad5-CMV-EGFP (2) or Ad5-CMV-AS-TGF-β1 (3) was assayed 
in duplicate for endogenous TGF-β1 transcripts (D) or alternatively for TGF-β1 and AS-TGF-β1 (E) using primer combina-
tions P1 and P2 (D) or P3 and P4 (E), respectively. Note, that small amounts of artificially synthesized DNA at higher cycle 
numbers occurring in the no-template control are due to primer dimer formation (4).BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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Double ligature model of the common bile duct in male rats of the Sprague-Dawley strain Figure 2
Double ligature model of the common bile duct in male rats of the Sprague-Dawley strain. (A) Under deep Ket-
amine-Rompun anesthesia the abdominal wall was shaved and a small incision with a scalpel was made. (B) The abdominal cav-
ity was opened, and selvages were stretched and fixated with two sterile high-grade steel tweezers. (C) Liver lobules were 
turned down and intestines were carefully pulled out. (D) The common bile duct was fixed with forceps and obstructed with a 
piece of string. (E) A second ligature was set in a distance of approximately 1 cm. (F) Intestines were into the abdominal cavity 
and the incision was replaced/sewn by several pinpricks. (G) The livers of sham-operated animals showed no sign of fibrosis at 
day 12 after surgery. (H) In contrast, in livers of animals receiving bile duct ligature a high degree of hepatic fibrosis is induced. 
Signs of ongoing liver fibrogenesis are the formation of oedema and fibrotic nodules on the surface of corresponding livers.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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(mean ± SD). In the course of obstructive cholestasis, the
values of individual animals were highest at day 2 after
ligature and were still increased by factors of approxi-
mately 100 (bilirubin), 6 (AST), and 5 (ALT) at day 12
compared to sham-operated controls.
Gene transfer of the antisense construct directed against 
TGF-β1 prevents liver fibrosis in the common bile duct 
ligature model
Recent reports describe that the transduction efficiency by
adenoviral mediated gene transfer is strongly reduced
after liver injury, but remained significant [28,29]. There-
fore, we decided to administrate the adenoviruses two
days prior setting of the injury followed by a booster injec-
tion at day 7 (5 days after BDL surgery). For histology,
blood sampling, and RNA/protein extraction animals
were sacrificed at day 14 corresponding to day 12 after
surgery (Fig. 3A). As documented in previous studies, the
administration of adenoviruses is an effective means to
direct transgene expression in liver as assessed by visual
detection of transduced EGFP under UV-light (not
shown). However, compared to normal controls, trans-
gene expression as assessed by delivery of an EGFP-
reporter was drastically reduced in the BDL cirrhotic rats
(Fig. 3B). To confirm successful transduction into liver
and proper expression of the antisense we performed PCR
allowing the amplification of a 225-bp fusion containing
sequences specific for TGF-β1 and the SV40-polyadenyla-
tion signal (Fig. 3C). We next tested whether Ad5-CMV-
AS-TGF-β1 infection was able to suppress liver fibrogene-
sis in BDL-treated rats. Therefore, we first quantified the
static levels of collagen by Sirius red staining (Fig. 4).
Impressively, the deposition of fibrillar collagen was sub-
stantially decreased in response to administration of the
antisense. This inhibitory effect was observed in all areas
of the liver, with no significant difference noticed between
the different lobules (not shown) while no reduction in
fibrosis was observed in Ad5-CMV-EGFP-treated rats. Also
the tendency for proliferation of biliary ductules in portal
areas was significantly reduced in injured livers expressing
the antisense (compare Figs. 4C and 4E). The morpholog-
ical evaluation of representative liver sections by two
independent pathologists revealed fibrosis scores with
increasing severity ranging from 0 (no BDL, saline), 1
(BDL, Ad5-CMV-AS-TGF-β1), and 3 (BDL, Ad5-CMV-
EGFP), respectively. Additionally, we demonstrate the
antifibrotic capacity of the transgene by its inhibitory
effects on α-SMA expression. In livers of BDL-treated rats,
the immunoreactivity for α-SMA as assessed by immuno-
histochemistry was significantly reduced by treatment
with the TGF-β1 antisense construct (Figs. 5A,5B,5C,5D).
To confirm and demonstrate the lowering in α-SMA
expression more quantitatively, we further performed
western blot analysis showing strong suppression of α-
SMA in animals treated with the transgene (Fig. 5E).
Again, these results indicate that Ad5-CMV-AS-TGF-β1
specifically inhibits ongoing fibrosis in liver.
In previous reports, the elimination of TGF-β signaling by
adenovirus-mediated local expression of a dominant-neg-
ative type II TGF-β receptor in the liver of rats treated with
dimethylnitrosamine was associated with serum levels of
liver specific transaminases comparable to normal con-
trols [11]. When we measured AST and ALT in the serum
of sacrificed rats which received BDL and gene transfer,
the levels of these hepatic enzymes were the same regard-
less of whether the BDL-treated rats were infused with
saline, Ad5-CMV-EGFP, or Ad5-CMV-AS-TGF-β1 indicat-
ing that the hepatic injury induced by BDL per se is not
influenced by TGF-β under the chosen experimental
conditions.
Discussion
In liver fibrogenesis TGF-β is the most potent profibro-
genic signaling factor triggering expression, accumulation
and deposition of collagen [30]. Elevated levels of TGF-β
are associated with altered lobular organisation, increase
of hepatocyte turnover and apoptosis [7–9]. Therefore,
mechanisms antagonizing TGF-β function or blocking
TGF-β synthesis are primary targets for directing antifi-
brotic therapies. In this view several approaches were
identified to abolish TGF-β signaling. These include
administration of antioxidants, specific drugs, herbal
compounds, neutralizing antibodies, TGF-β binding pro-
teins (scavengers), antagonistic cytokines, suppressors of
apoptosis, or specifically designed oligonucleotides [2].
Another promising approach is the inhibition of proteo-
lytic release and activation of latent TGF-β. Representa-
tive, the serine protease inhibitor camostat mesilate was
recently found to suppress HSC activation by inhibiting
hepatic plasmin activity and thereby preventing hepatic
fibrosis [31]. Presently, potential gene therapies using
dominant negative or soluble TβR-II are under close inves-
tigation. Because TβR-II is the primary binding receptor
for TGF-β, overexpression of an inactive TβR-II construct
counters TGF-β actions. The development of hepatic
fibrosis by dimethylnitrosamine (DMN) in rats was mark-
edly reduced by adenoviral vectors expressing either a
truncated human TβR-II injected via the portal vein [11]
or soluble human TGF-β receptors (a chimeric protein
between an entire ectodomain of human TβR-II and the Fc
portion of human immunoglobulin G) injected intramus-
cularly [13]. Impressively, a single injection of adenovirus
expressing the truncated receptor, given prior to DMN
administration, appeared to prevent both hepatic injury
and the development of hepatic fibrosis. In a subsequent
study, the same adenoviral vector was administered to
animals with ongoing fibrosis after 3 weeks of DMN in
order to determine whether reversal of fibrosis occurs with
this agent. The results were similar with lack ofBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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progression and possibly some regression of hepatic fibro-
sis in rats that received the dominant negative receptor
[12]. The antifibrogenic potential of soluble TβR-II was
also demonstrated in the rat bile duct ligature model by
slow infusion of the chimeric proteins into the femoral
vein [32]. Another option to inhibit TGF-β function is to
interfere with postreceptor signaling. Overexpression of
Smad7, a natural antagonist of TGF-β signaling, prevents
bleomycin induced pulmonary fibrosis in mice [16] and
was recently shown to prevent activation of hepatic stel-
late cells and liver fibrosis in rats [33].
The present work evaluates the potency of an antisense
mRNA complementary to the 3' coding sequence of TGF-
β1 in preventing liver fibrogenesis during obstructive bile
duct ligature in rat. The efficacy of the expressed antisense
Time course for experimental testing of antifibrotic devices directed against TGF-β Figure 3
Time course for experimental testing of antifibrotic devices directed against TGF-β. (A) Male Sprague-Dawley 
rats were given a single infusion of either Ad5-CMV-AS-TGF-β1, Ad5-CMV-EGFP, or phosphate buffered saline at day 0 and a 
replenishment infusion at day 7. Two days after the first injection, the animals were subjected to bile duct ligation (BDL). At 
day 12, animals were sacrificed for liver histology and sampling of protein and RNA specimens. (B) Transfer of adenoviruses 
into normal and injured livers. A reporter adenovirus expressing the green fluorescent protein (EGFP) was injected two days 
prior surgery via the tail vein. Four days after surgery, the livers were homogenized, and 20 µg of protein samples each were 
tested for expression of EGFP by Western blot analysis. Note the lower level of transgene expression in animals that received 
bile duct ligature. (C) Transduction of AS-TGF-β1 in normal and injured livers in vivo. Liver injury was induced by BDL and ade-
noviruses (1 × 1010 pfu/kg) were administered to normal or injured rats two days prior BDL. Liver samples were analyzed for 
expression of the transgene by RT-PCR.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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Histology of livers from rats subjected to BDL Figure 4
Histology of livers from rats subjected to BDL. Rats were infused via the tail vein with saline (A, B), Ad5-CMV-EGFP 
(C, D), or Ad5-CMV-AS-TGF-β1 (E, F). The animalswere subjected to BDL (C-F) or were sham-operated (A, B) according 
to the time course outlined in Fig. 3A. Liver sections were examined histologically by hematoxylin (A, C, E) or Sirius red (B, 
D, F) staining. Note the fibrous expansion of portal areas with occasional portal to portal bridging in (D) and reduced fibrosis 
showing only marginal fibrous expansion in the portal areas without septa in (F). Original magnifications are ×100 (A, B) and 
×200 (C-F).BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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to block TGF-β synthesis in culture-activated HSC was pre-
viously shown by immunoprecipitation, Western blot,
quantitative TGF-β1 ELISA, and cell proliferation assays
[17]. We here demonstrate that the in vitro synthesized
quantities of the expressed transgene delivered by an ade-
noviral vector exceed endogenous levels of TGF-β1
mRNAs by several orders of magnitude. To verify the effi-
cacy of the antisense we determined collagen and α-SMA
as markers in an experimental in vivo model of liver fibro-
genesis. In this experimental model of obstructive hepatic
injury, damage was induced by ligature of the common
bile duct leading to a drastic accumulation of collagen
content in the liver. Delivery of the antisense complemen-
tary to TGF-β1 mRNA prevented the deposition of colla-
gen as assessed by histochemistry using Sirius red
staining. Further, in animals receiving the transgene, we
found also reduced expression of α-SMA in histological
sections and protein extracts analyzed by western blot.
Previous studies examined the role of TGF-β inhibition on
hepatic fibrogenesis induced by bile duct ligation, using
soluble TβRII constructs sequestering TGF-β. In one report
it was demonstrated that the soluble receptor was able to
reduce collagen and α-SMA quantities when given at the
time of injury or given at day 4 after injury [32]. The
authors concluded that soluble TGF-β receptor is an effec-
tive inhibitor in vivo and merits clinical evaluation as a
novel agent for controlling hepatic fibrosis in chronic liver
injury [32]. However, the chimeric fusion consisting of
the extracellular domain of TβRII with the Fc portion of an
immunoglobulin might create potent epitopes and
thereby preventing its repetitive application for longer
time periods. Therefore, the finding that an antisense
complementary to endogenous TGF-β1 mRNA has the
α-SMA expression in liver Figure 5
α-SMA expression in liver. Rats were treated as 
described in the legend to Fig. 3. (A) In normal livers, α-SMA 
positivity was noted in smooth muscle cells of portal tract 
vessels and in a few cells surrounding terminal hepatic 
venules. (B, C) In BDL animals infected with the control 
virus (Ad5-CMV-EGFP), livers were highly enriched in α-
SMA-positive HSC forming layers around the bile ductules. In 
addition, α-SMA positive cells in the periportal sinusoids 
were visible in the vicinity of ductular areas, consistent with 
the active recruitment of activated HSC by ductular struc-
tures.(D) BDL animals infected with Ad5-CMV-AS-TGF-β1 
showed no significant increase in α-SMA staining. (E) Immu-
noblot analysis of α-SMA expression in livers of BDL rats (1-
3), BDL rats infected with Ad5-CMV-AS-TGF-β1 (4–6), or 
normal control rats (7). As a positive control a total lysate 
from culture-activated HSC expressing high levels of the 42-
kD α-SMA was loaded (8). Original magnifications are ×200 
(A, D), ×100 (B), and ×400 (C), respectively.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/29
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same beneficial antifibrotic capacity may offer considera-
ble promise to alleviate TGF-β induced damages during
chronic liver diseases and increase the safety of future
intervention strategies by diminishing the risk of avoida-
ble immune responses.
However, we have not yet analyzed the consequences of
long-term systemic exposure to the TGF-β antisense, par-
ticular in regard to systemic effects like body weight,
deterioration of a clinical status, or the likelihood of
increased spontaneous tumorigenesis and immune sys-
tem dysfunctions. Moreover, we have no estimation of
how much active TGF-β is still present in liver cells of Ad5-
CMV-AS-TGF-β1-infected animals. Complementary
future studies are necessary to address these critical issues.
Conclusions
We conclude that our data gives strong evidence that the
transfer of the designed TGF-β1 antisense is sufficient to
specifically abolish the diverse effects of TGF-β in ongoing
hepatic fibrogenesis. Therefore, the antisense strategy is
attractive as a therapeutic agent for preventing stellate cell
activation and may help clarify the role of TGF-β in this
process both in vitro and in vivo. Moreover, the antisense
technology may provide opportunities for the treatment
of chronic liver diseases.
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